Success Metrics

Clinical Success Rate
84.7%

Based on 72 completed trials

Completion Rate
85%(72/85)
Active Trials
12(10%)
Results Posted
56%(40 trials)
Terminated
13(10%)

Phase Distribution

Ph early_phase_1
1
1%
Ph not_applicable
4
3%
Ph phase_1
22
18%
Ph phase_2
55
44%
Ph phase_3
19
15%
Ph phase_4
10
8%

Phase Distribution

23

Early Stage

55

Mid Stage

29

Late Stage

Phase Distribution111 total trials
Early Phase 1First-in-human
1(0.9%)
Phase 1Safety & dosage
22(19.8%)
Phase 2Efficacy & side effects
55(49.5%)
Phase 3Large-scale testing
19(17.1%)
Phase 4Post-market surveillance
10(9.0%)
N/ANon-phased studies
4(3.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.8%

72 of 87 finished

Non-Completion Rate

17.2%

15 ended early

Currently Active

12

trials recruiting

Total Trials

125

all time

Status Distribution
Active(18)
Completed(72)
Terminated(15)
Other(20)

Detailed Status

Completed72
unknown19
Terminated13
Recruiting8
Not yet recruiting5
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
125
Active
12
Success Rate
84.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.9%)
Phase 122 (19.8%)
Phase 255 (49.5%)
Phase 319 (17.1%)
Phase 410 (9.0%)
N/A4 (3.6%)

Trials by Status

terminated1310%
active_not_recruiting43%
completed7258%
suspended11%
recruiting86%
withdrawn22%
enrolling_by_invitation11%
not_yet_recruiting54%
unknown1915%

Recent Activity

Clinical Trials (125)

Showing 20 of 125 trialsScroll for more
NCT07113743Phase 1

Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

Enrolling By Invitation
NCT07687134Phase 2

Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP

Not Yet Recruiting
NCT07660172Phase 2

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

Not Yet Recruiting
NCT05653219Phase 3

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Active Not Recruiting
NCT04518475Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Recruiting
NCT02099747Phase 3

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Completed
NCT01328587Phase 2

Eltrombopag for Moderate Aplastic Anemia

Completed
NCT04837703

Managed Access Programs for ETB115, Eltrombopag

Unknown
NCT04797000Phase 2

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Active Not Recruiting
NCT06345495Phase 2

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Recruiting
NCT04304820Phase 2

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Recruiting
NCT06287268

Revolade Tablets Specified Drug-use Survey

Recruiting
NCT03664518Phase 2

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

Completed
NCT04328727Phase 2

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Completed
NCT03988608Phase 2

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Completed
NCT03948529Phase 2

RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation

Terminated
NCT07189910Phase 4

Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

Not Yet Recruiting
NCT05438875Phase 3

The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

Completed
NCT03206086Phase 2

Eltrombopag for People With Fanconi Anemia

Active Not Recruiting
NCT07093606Not Applicable

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
125